InMode (NASDAQ:INMD) Shares Gap Up - Should You Buy?

Key Points

• Shares gapped up on Friday, opening at $13.71 from a $12.76 close and last trading around $13.59 on heavy volume (~653,419 shares); the stock trades below its 50- and 200-day moving averages (~$14.43 and $14.64) with a market cap of ~$855M and a P/E of 9.35.
• Analyst sentiment is lukewarm—consensus rating is Hold (1 Buy, 7 Hold, 1 Sell) with a consensus price target of $16.80.
• InMode reported quarterly EPS of $0.46, beating estimates by $0.04, while revenue of $103.85M slightly missed consensus; the company reported strong profitability metrics (net margin 25.33%, ROE 14.52%).

InMode Ltd. (NASDAQ:INMD - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $12.76, but opened at $13.71. InMode shares last traded at $13.5850, with a volume of 653,419 shares.

Analyst Ratings Changes

INMD has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of InMode in a research note on Thursday, January 22nd. BTIG Research reissued a "neutral" rating on shares of InMode in a report on Monday, January 26th. Robert W. Baird set a $17.00 price target on shares of InMode in a report on Wednesday, February 11th. Finally, Canaccord Genuity Group set a $15.00 price objective on shares of InMode and gave the company a "hold" rating in a report on Wednesday, December 17th. One analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $16.80.

InMode Price Performance

The company has a 50-day moving average of $14.43 and a two-hundred day moving average of $14.64. The stock has a market capitalization of $855.11 million, a PE ratio of 9.35 and a beta of 2.18.

InMode (NASDAQ:INMD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The healthcare company reported $0.46 EPS for the quarter, beating analysts' consensus estimates of $0.42 by $0.04. InMode had a net margin of 25.33% and a return on equity of 14.52%. The company had revenue of $103.85 million during the quarter, compared to the consensus estimate of $104.64 million. During the same quarter in the prior year, the company posted $0.42 EPS. The company's quarterly revenue was up 6.1% compared to the same quarter last year. On average, research analysts forecast that InMode Ltd. will post 1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On InMode

A number of large investors have recently modified their holdings of INMD. Leonteq Securities AG acquired a new position in InMode during the 4th quarter worth approximately $26,000. Quadrant Capital Group LLC raised its stake in shares of InMode by 127.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company's stock valued at $29,000 after purchasing an additional 1,091 shares during the period. Advisory Services Network LLC acquired a new position in shares of InMode during the third quarter worth $37,000. Basepoint Wealth LLC acquired a new position in shares of InMode during the fourth quarter worth $39,000. Finally, Blue Trust Inc. boosted its stake in shares of InMode by 93.7% in the third quarter. Blue Trust Inc. now owns 2,861 shares of the healthcare company's stock valued at $43,000 after purchasing an additional 1,384 shares during the period. Institutional investors and hedge funds own 68.04% of the company's stock.

InMode Company Profile

InMode Ltd. NASDAQ: INMD is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode's product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.